Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06336343 · ClinicalTrials.gov registry record · Phase 4
Bimekizumab in Plaque Psoriasis
A Phase 4 study of Plaque Psoriasis, sponsored by Icahn School of Medicine at Mount Sinai.
- Recruiting
- Registry status
- Phase 4
- Development phase
- 60
- Enrollment target
- 2
- Study locations
NCT06336343 is a Phase 4 study of Plaque Psoriasis that is actively recruiting participants, run by Icahn School of Medicine at Mount Sinai. The registered enrollment target is 60 participants, below the 415-participant average among 45 other Plaque Psoriasis trials with a reported enrollment target (86% lower). The trial reports 2 study locations across 2 states.
The verdict
NCT06336343, a Phase 4 study of Plaque Psoriasis, is actively recruiting participants, sponsored by Icahn School of Medicine at Mount Sinai.
- RECRUITING
- Registry status
- Phase 4
- Development phase
- 60 participants
- Enrollment target
- 2
- Study locations
Study Summary
The purpose of this research study is to evaluate the effectiveness and safety of bimekizumab in individuals with moderate-to-severe psoriasis who have failed similar therapies. Bimekizumab improves psoriasis by suppressing a type of substance found in bodies called interleukins (specifically, interleukins 17a and 17F), which are known to increase inflammation. This study will look at the effectiveness of bimekizumab in psoriasis patients that have failed previous therapies that target interleukin IL-17A or 23.
Conditions Studied
Interventions
- DRUG Bimekizumab
Study Locations (2)
New Jersey
- Windsor Dermatology - Psoriasis Treatment Center of Central New Jersey - East Windsor
New York
- Icahn School of Medicine at Mount Sinai - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2024-06-03 |
| Est. Completion | 2026-03-13 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06336343
The ClinicalTrials.gov registry entry for NCT06336343 describes a study currently listed as recruiting, categorized as Phase 4. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 415-participant average among 45 other Plaque Psoriasis trials with a reported enrollment target (86% lower). The listed sponsor is Icahn School of Medicine at Mount Sinai, which has 708 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Plaque Psoriasis appearing as the primary indexed condition, and to 1 intervention - of which Bimekizumab is the first listed.
NCT06336343 reports 2 study locations spanning 2 distinct geographic areas - top geographies include New Jersey, New York.
Frequently Asked Questions
What is clinical trial NCT06336343 about?
NCT06336343 is a clinical study titled "Bimekizumab in Plaque Psoriasis". The purpose of this research study is to evaluate the effectiveness and safety of bimekizumab in individuals with moderate-to-severe psoriasis who have failed similar therapies. Bimekizumab improves psoriasis by suppressing a type of substance found in bodies called interleukins (specifically, inter...
What is the current status of trial NCT06336343?
This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 60 participants. The study started on 2024-06-03. Estimated completion is 2026-03-13.
What conditions does trial NCT06336343 study?
This clinical trial studies the following conditions: Plaque Psoriasis.
What interventions are being tested in trial NCT06336343?
The interventions under investigation include: Bimekizumab (DRUG).
Who is sponsoring clinical trial NCT06336343?
This trial is sponsored by Icahn School of Medicine at Mount Sinai, which has 708 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06336343 being conducted?
This trial has 2 study locations across New Jersey, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Plaque Psoriasis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Guselkumab Immunogenetics
RECRUITING · Phase 4
-
Patient Preference of Taclonex Ointment to Taclonex Scalp Suspension in Adult Subjects With Psoriasis Vulgaris
COMPLETED · Phase 4
-
Adrenal Suppression and Absorption Study of Halobetasol Propionate Foam in Subjects 12-17 With Plaque Psoriasis
COMPLETED · Phase 4
-
Patient Satisfaction Following Twice Daily Dosing With DFD-01 in Subjects With Moderate Plaque Psoriasis
COMPLETED · Phase 4
-
Subject Reported Target-lesion Numeric Rating Scale Evaluation by Subjects With Plaque Psoriasis Treated With Clobex® (Clobetasol Propionate) Spray 0.05%
COMPLETED · Phase 4
-
Long-Term Safety Study of Deucravacitinib Versus Ustekinumab in Participants With Psoriasis (PRAGMATYK)
RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.